151 related articles for article (PubMed ID: 34895843)
21. Pharmacokinetics of posaconazole prophylaxis of patients with acute myeloid leukemia.
Mattiuzzi G; Yilmaz M; Kantarjian H; Borthakur G; Konopleva M; Jabbour E; Brown Y; Pierce S; Cortes J
J Infect Chemother; 2015 Sep; 21(9):663-7. PubMed ID: 26141814
[TBL] [Abstract][Full Text] [Related]
22. Real-world effectiveness of antifungal prophylaxis with posaconazole as the primary agent in patients with haematological malignancies.
Strand AM; Alexander BD; Sarpong E; Wong JR; Engemann A; Rizzieri D; Wu Y; Johnson MD
Mycoses; 2022 Nov; 65(11):1050-1060. PubMed ID: 35816393
[TBL] [Abstract][Full Text] [Related]
23. Is Posaconazole Really Effective in Adolescent patients as a Prophylactic Agent: Experience of a Tertiary Care Center.
Arikan K; Aytac S; Büyükcam A; Cengiz AB; Cetinkaya FD; Cetin M; Ozsurekci Y; Ceyhan M; Kara A
J Pediatr Hematol Oncol; 2021 Jul; 43(5):e613-e618. PubMed ID: 33560081
[TBL] [Abstract][Full Text] [Related]
24. Effectiveness of primary anti-Aspergillus prophylaxis during remission induction chemotherapy of acute myeloid leukemia.
Gomes MZ; Jiang Y; Mulanovich VE; Lewis RE; Kontoyiannis DP
Antimicrob Agents Chemother; 2014 May; 58(5):2775-80. PubMed ID: 24590477
[TBL] [Abstract][Full Text] [Related]
25. Comparison of invasive fungal diseases between patients with acute myeloid leukemia receiving posaconazole prophylaxis and those not receiving prophylaxis: A single-center, observational, case-control study in South Korea.
Yang E; Choi EJ; Park HS; Lee SO; Choi SH; Kim YS; Lee JH; Lee JH; Lee KH; Kim SH
Medicine (Baltimore); 2021 May; 100(20):e25448. PubMed ID: 34011022
[TBL] [Abstract][Full Text] [Related]
26. Invasive fungal infections in AML/MDS patients treated with azacitidine: a risk worth considering antifungal prophylaxis?
Pomares H; Arnan M; Sánchez-Ortega I; Sureda A; Duarte RF
Mycoses; 2016 Aug; 59(8):516-9. PubMed ID: 27027972
[TBL] [Abstract][Full Text] [Related]
27. Isavuconazonium or posaconazole for antifungal prophylaxis in patients with acute myeloid leukemia.
White O; Kennedy E; Huckabee JB; Rogers E; LeBlanc TW; Dillon M; Li Z; Hanna D
J Oncol Pharm Pract; 2024 Apr; 30(3):527-534. PubMed ID: 37186784
[TBL] [Abstract][Full Text] [Related]
28. Incidence of Invasive Fungal Infections in Acute Myeloid Leukemia Without Antifungal Prophylaxis.
Signorelli J; Lei M; Lam J; Jalbut M; Amrein PC; Fathi AT; Hobbs G; Hock H; McAfee SL; Letourneau AR; Narayan R; Brunner A
Clin Lymphoma Myeloma Leuk; 2020 Nov; 20(11):e883-e889. PubMed ID: 32917574
[TBL] [Abstract][Full Text] [Related]
29. Itraconazole vs. posaconazole for antifungal prophylaxis in patients with acute myeloid leukemia undergoing intensive chemotherapy: A retrospective study.
Copley MS; Waldron M; Athans V; Welch SC; Brizendine KD; Cober E; Siebenaller C
Int J Antimicrob Agents; 2020 Mar; 55(3):105886. PubMed ID: 31926286
[TBL] [Abstract][Full Text] [Related]
30. Posaconazole vs. fluconazole as invasive fungal infection prophylaxis in China: a multicenter, randomized, open-label study.
Shen Y; Huang XJ; Wang JX; Jin J; Hu JD; Yu K; Wu DP; Wang SJ; Yu L; Chen XQ; Liu T; Liang YM; Chen FP; Li Y; Shen ZX
Int J Clin Pharmacol Ther; 2013 Sep; 51(9):738-45. PubMed ID: 23924680
[TBL] [Abstract][Full Text] [Related]
31. Pharmacoeconomic evaluation of voriconazole versus posaconazole for antifungal prophylaxis in acute myeloid leukaemia.
Al-Badriyeh D; Slavin M; Liew D; Thursky K; Downey M; Grigg A; Bajel A; Stewart K; Kong DC
J Antimicrob Chemother; 2010 May; 65(5):1052-61. PubMed ID: 20237074
[TBL] [Abstract][Full Text] [Related]
32. [Prophylaxis use of posaconazole (P) in an hemato-oncology unit: a retrospective study].
Selvy N; Villiet M; Hansel-Esteller S
Pathol Biol (Paris); 2010 Apr; 58(2):123-6. PubMed ID: 19864087
[TBL] [Abstract][Full Text] [Related]
33. High incidence of invasive fungal infection during acute myeloid leukemia treatment in a resource-limited country: clinical risk factors and treatment outcomes.
Nganthavee V; Phutthasakda W; Atipas K; Tanpong S; Pungprasert T; Dhirachaikulpanich D; Krithin S; Tanglitanon S; Jutidamronphang W; Owattanapanich W; Chayakulkeeree M; Phikulsod P
Support Care Cancer; 2019 Sep; 27(9):3613-3622. PubMed ID: 31165931
[TBL] [Abstract][Full Text] [Related]
34. Management of Invasive Fungal Infections in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: The Turin Experience.
Busca A; Cinatti N; Gill J; Passera R; Dellacasa CM; Giaccone L; Dogliotti I; Manetta S; Corcione S; De Rosa FG
Front Cell Infect Microbiol; 2021; 11():805514. PubMed ID: 35071052
[TBL] [Abstract][Full Text] [Related]
35. Breakthrough Invasive Fungal Infections in Patients with Acute Myeloid Leukemia.
Wasylyshyn A; Linder KA; Castillo CG; Zhou S; Kauffman CA; Miceli MH
Mycopathologia; 2020 Apr; 185(2):299-306. PubMed ID: 31939052
[TBL] [Abstract][Full Text] [Related]
36. Invasive Fungal Infections in Children With Acute Myeloid Leukemia: A Single-center Experience Over 19 Years.
Avcu G; Karadas N; Goktepe SO; Bal ZS; Metin DY; Polat SH; Aydinok Y; Karapinar DY
J Pediatr Hematol Oncol; 2023 Oct; 45(7):392-397. PubMed ID: 37526370
[TBL] [Abstract][Full Text] [Related]
37. Impact of fluconazole versus posaconazole prophylaxis on the incidence of fungal infections in patients receiving induction chemotherapy for acute myeloid leukemia.
Devanlay C; Tavernier-Tardy E; Bourmaud A; Falk AT; Raberin H; Menguy S; Guyotat D; Magné N; Cornillon J
Biomed J; 2015; 38(3):235-43. PubMed ID: 25355388
[TBL] [Abstract][Full Text] [Related]
38. Antifungal prophylaxis in newly diagnosed AML patients-Adherence to guidelines and feasibility in a real life setting.
Berking S; Doedens D; Horns H; Fiegl M; Ostermann H; Rieger CT
Mycoses; 2017 Sep; 60(9):600-606. PubMed ID: 28504318
[TBL] [Abstract][Full Text] [Related]
39. Clinical effectiveness of itraconazole as antifungal prophylaxis in AML patients undergoing intensive chemotherapy in the modern era.
Keighley CL; Manii P; Larsen SR; van Hal S
Eur J Clin Microbiol Infect Dis; 2017 Feb; 36(2):213-217. PubMed ID: 27830376
[TBL] [Abstract][Full Text] [Related]
40. Serum posaconazole levels during acute myeloid leukaemia induction therapy: correlations with breakthrough invasive fungal infections.
Cattaneo C; Panzali A; Passi A; Borlenghi E; Lamorgese C; Petullà M; Re A; Caimi L; Rossi G
Mycoses; 2015 Jun; 58(6):362-7. PubMed ID: 25907298
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]